Kedrion Biopharma News and Resources

Kedrion Biopharma has announced that its manufacturing facility in Bolognana, Italy, has been approved by the U.S. Food and Drug Administration (FDA) to produce RYPLAZIM, a plasma-derived treatment for plasminogen deficiency type 1 (PLGD-1). This rare chronic condition primarily causes